Neuroethics and psychiatry: New collaborations for emerging challenges

Psychiatric Annals

Volumn 37, Issue 12, 2007, Pages 798-804

  Murphy, Emily R ^a,d   Illles, Judy ^b,c  

^a STANFORD LAW SCHOOL   (United States)

^b Department of Neurology ^*

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d Stanford Center for International Law and Cooperation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 38849206974     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/00485713-20071201-03     Document Type: Article

References (41)

1. Illes J. Neuroethics, Neurochallenges: A Needs-Based Research Agenda. In: Society for Neuroscience. Atlanta, GA; 2006.
2. National Commission for the Protection of Human Subjects. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Government Printing Office, Washington, DC: 1978.
3. National Bioethics Advisory Commission. Ethical and Policy Issues in Research Involving Human Participants. Washington, DC; 2001.
4. National Bioethics Advisory Commission. Research Involving Persons with Mental Disorders that may Affect Decision-making Capacity. Washington, DC; 1998.
5. Miller F, Fins JJ. Protecting subjects in brain research: a pragmatic perspective. In: Neuroethics: Defining the Issues in Theory, Practice and Policy. Illes J, ed. Oxford University Press: Oxford, UK; 2006:123-140.
6. Illes J, Kirschen MP, Edwards E, et al, and the Working Group on Incidental Findings in Brain Imaging Research. Ethics: incidental findings in brain imaging research. Science. 2006;311(5762)783-784.
7. Farah MJ, Wolpe PR. Monitoring and manipulating brain function: new neuroscience technologies and their ethical implications. Hastings Cent Rep. 2004;34(3):35-45.
8. Kolber A. Therapeutic forgetting: the legal and ethical implications of memory dampening. Vanderbilt Law Review. 2006;59(5):1561-1626.
9. Glannon W. Psychopharmacology and memory. J Med Ethics. 2006;32(2):74-78.
10. Henry M, Fishman JR, Youngner SJ. Propranolol and the prevention of post-traumatic stress disorder: is it wrong to erase the "sting" of bad memories? Am J Bioeth. 2007;7(9):12-20.
11. Evers K. Perspectives on memory manipulation: using beta-blockers to cure post-traumatic stress disorder. Camb Q Healthc Ethics. 2007;16(2): 138-146.
12. Debiec J, Altemus M. Toward a new treatment for traumatic memories. Cerebrum. 2006:2-11.
13. Cahill L, Prins P, Weber M, McGaugh JL. Betaadrenergic activation and memory for emotional events. Nature. 1994;371(6499):702-704.
14. Reist C, Duffy JG, Fujimoto K, Cahill L. Beta-adrenergic blockade and emotional memory in PTSD. Int J Neuropsychopharmacot. 2001;4(4):377-383.
15. Maheu FS, Joober R, Lupien SJ. Declarative memory after stress in humans: differential involvement of the beta-adrenergic and corticosteroid systems. J Clin Endocrinol Metab. 2005;90(3):1697-1704.
16. Pitman RK, Sanders KM, Zusman RM, et al.Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry. 2002;51 (2): 189-192.
17. Vaiva G, Ducrocq F, Jezekel K, et al. Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma. Biol Psychiatry. 2003;54(9):947-949.
18. Tenenbaum EM, Reese B. Memory-altering drugs: shifting the paradigm of informed consent. Am J Bioeth. 2007;7(9):40-42.
19. Am J Bioeth. 2007;7(9).
20. Debiec J, LeDoux JE. Noradrenergic signaling in the amygdala contributes to the reconsolidation of fear memory: treatment implications for PTSD. Ann NY Acad Sci. 2006;1071:521-524.
21. Przybyslawski J, Roullet P, Sara SJ. Attenuation of emotional and nonemotional memories after their reactivation: role of beta adrenergic receptors. J Neurosci. 1999;19(15):6623-6628.
22. Brunet A, Orr SP, Trembaly J, Robertson K, Nader K, Pitman RK. Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder. J Psychiatr Res. 2007; June 21 (e-pub).
23. President's Council on Bioethics. Beyond Therapy. President's Council on Bioethics/ Harper Collins: Washington, DC. 2003:328.
24. Mayberg HS, Lozano AM, Voon V, et al. Deep brain stimulation for treatment-resistant depression. Neuron. 2005;45(5):651-660.
25. Rau A, Grossheinrich N, Palm U, Pogarell O, Padberg F. Transcranial and deep brain Stimulation approaches as treatment for depression. Clin EEG Neurosa. 2007;38(2): 105-115.
26. O'Reardon JP Solvason HB, Janicak PG, et al, Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry. 2007;62(11):1208-1216.
27. Steven MS, Pascual-Leone A. TMS in the human brain: An ethical evaluation. In: Neuroethics: Defining the Issues in Theory, Practice, and Policy. Dies J, ed. Oxford University Press: New York; 2006:201.
28. Abou-Saleh MT. Neuroimaging in psychiatry: an update. JPsychosom Res. 2006;61(3):289-293.
29. Hariri AR, Weinberger DR. Imaging genomics. Br Med Bull. 2003;65:259-270.
30. Roffman JL, Weiss AP, Goof DC, Rauch SL, Weinberger DR. Neuroimaging-genetic paradigms: A new approach to investigate the pathophysiology and treatment of cognitive deficits in schizophrenia. Harv Rev Psychiatry. 2006;14(2):78-91.
31. Berger M, Wagner TH, Baker LC. Internet use and stigmatized illness. Soc Sci Med. 2005;61(8):1821-1827.
32. Illes J, et al., Beyond the anatomo-functional benefits of neuroimaging for major depression. Society for Neuroscience Annual Meeting. November 2007; San Diego, CA.
33. Mehta MA, Owen AM, Sahakian BJ, Mavaddat N, Pickard JD, Robbins TW. Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J Neurosci. 2000;20(6):RC65.
34. Hall SS. The quest for a smart pill. Sci Am. 2003;289(3):54-65.
35. Lynch G. Memory enhancement: The search for mechanism-based drugs. Nat Neurosci. 2002;5(Suppl): 1035-1038.
36. Teitelman E. Off-label uses of modafinil. Am J Psychiatry. 2001;158(8):1341.
37. Turner DC, Robbins TW, Clark L, Aron AR, Dowson J, Sahakian BJ. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology (Berl). 2003;165(3):260-269.
38. Farah MJ, liles J, Cook-Deegan R, et al. Neurocognitive enhancement: what can we do and what should we do? Nat Rev Neurosci. 2004;5(5):421-425.
39. Loh A, Leonhart R, Wills CE, Härter M. The impact of patient participation on adherence and clinical outcome in primary care of depression. Patient Educ Counsel. 2006;65(1):69-78.
40. Simon D, et al. Depressed patients' perception of depression treatment decision-making. Health Expectations. 2006;10:62-74.
41. Murray E, Pollack L, White M, Lo B. Clinical decision-making: physicians' preferences and experiences. BMC Fam Pract. 2007;8:10.